Copertina

Editorial: Peroxisome Proliferator‐Activated Receptor Agonists—Shifting the Goalpost From Biochemical Response to Symptom Directed Therapy in PBC

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Henry H. Nguyen, Mark G. Swain
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
di: Jörn M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
di: Joëlle St‐Pierre, et al.
Pubblicazione: (2026)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2024)

Editorial: UDCA Dosing in PBC – Between Guideline Adherence and Clinical Reality
di: Helena Hernández‐Évole, et al.
Pubblicazione: (2026)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
di: Maryam Zafer, et al.
Pubblicazione: (2025)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
di: Ellen Werner, et al.
Pubblicazione: (2026)

Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
di: Sydney Pomenti, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
di: Christophe Corpechot
Pubblicazione: (2026)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?
di: Alessandro Granito, et al.
Pubblicazione: (2026)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
di: Benjamin Douglas Liu, et al.
Pubblicazione: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
di: Linda Henry, et al.
Pubblicazione: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
di: Mazen Noureddin, et al.
Pubblicazione: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
di: Wen‐Juei Jeng, et al.
Pubblicazione: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
di: Christopher L. Bowlus, et al.
Pubblicazione: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
di: Eunice Yewon Lee, et al.
Pubblicazione: (2024)

Editorial: Right‐Sizing Colonoscopy Referrals for Patients With Possible Signs and Symptoms of Colorectal Cancer
di: Nicole P. Mirabadi, et al.
Pubblicazione: (2025)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply
di: Natassia Tan, et al.
Pubblicazione: (2025)

Letter: Shifting focus—From ChatGPT to specialised medical LLMs
di: Shuo Wang, et al.
Pubblicazione: (2024)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
di: Arshdeep Singh, et al.
Pubblicazione: (2025)

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
di: Alessandro Molinaro, et al.
Pubblicazione: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
di: Emily Stephenson, et al.
Pubblicazione: (2026)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
di: Maxim S. Petrov
Pubblicazione: (2026)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
di: Darcy Quinn Holt, et al.
Pubblicazione: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance
di: Apichat Kaewdech, et al.
Pubblicazione: (2026)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
di: C. Ramos‐Belinchon, et al.
Pubblicazione: (2025)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
di: Eunice X. X. Tan, et al.
Pubblicazione: (2024)

Editorial: Safety and Effects of Direct Oral Anticoagulants for Portal Vein Thrombosis
di: Nina Kimer, et al.
Pubblicazione: (2025)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
di: Vincent Haghnejad, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
di: Eric Lawitz, et al.
Pubblicazione: (2025)